SAN FRANCISCO–(BUSINESS WIRE)–LightSource, an AI-powered sourcing platform built for enterprise procurement, announced today that it has been named to The HackettSAN FRANCISCO–(BUSINESS WIRE)–LightSource, an AI-powered sourcing platform built for enterprise procurement, announced today that it has been named to The Hackett

LightSource Named to The Hackett Group’s 2026 50 to Watch

2026/02/24 23:36
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

SAN FRANCISCO–(BUSINESS WIRE)–LightSource, an AI-powered sourcing platform built for enterprise procurement, announced today that it has been named to The Hackett Group’s 2026 50 to Watch as part of its annual assessment of the global procurement technology market. The program recognizes emerging, leading and enduring solution providers shaping the procurement technology market.

The lists are compiled by The Hackett Group’s Solution Intelligence analysts, formerly the Spend Matters™ analyst team. Selection is informed by year-round market monitoring, detailed briefings, product demonstrations and direct engagement with procurement technology providers. Vendor evaluation follows a rigorous, data-driven approach based on criteria, including technology capability, solution maturity, innovation, customer adoption and overall market impact.

“LightSource is an AI-native sourcing platform that is purpose-built to address direct materials procurement, especially the complexity of part- and BoM-driven sourcing,” said Bertrand Maltaverne, Lead Analyst, Upstream Procurement, The Hackett Group. “LightSource empowers sourcing teams with data and insights rather than replacing human decision-making. Its focused innovation, modern architecture and traction in complex manufacturing categories earn LightSource its place among the 50 to Watch.”

For the 2025–2026 lists, The Hackett Group® evaluated approximately 220 procurement technology vendors globally. Eligibility for inclusion was based on participation in product demonstrations, enabling a consistent and objective assessment across all vendors evaluated. This year’s evaluation reflects a rapidly evolving procurement technology landscape, with AI-enabled capabilities now widely embedded across platforms and solution categories. As organizations seek measurable outcomes from technology investments, differentiation is increasingly driven by how effectively providers translate innovation into practical, scalable results.

“We are honored to be recognized by The Hackett Group on its 50 to Watch list of procurement providers,” said Spencer Penn, CEO and Co-Founder of LightSource. “LightSource was founded to close a critical gap in procurement technology for Direct Materials. Even though Direct accounts for the majority of external spend, it remains the most underserved area in the procuretech space. We’re changing that.”

Find the full lists and more information about The Hackett Group’s procurement technology assessment program here.

About LightSource

LightSource is the only direct materials sourcing platform, designed for enterprise procurement professionals and their suppliers, that automates the entire sourcing process – from supplier discovery to award – enabling buyers to achieve significant efficiency gains, better sourcing outcomes through AI-powered insights, and improved collaboration, while also providing suppliers with a user-friendly platform to win new business. For more information, visit lightsource.ai

Contacts

Media Contacts
Public Relations
LightSource
lightsource@colabcomms.co

Market Opportunity
Particl Logo
Particl Price(PART)
$0.157
$0.157$0.157
-1.31%
USD
Particl (PART) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09